摘要
目的:观察大剂量静脉输注甲钴胺预防硼替佐米治疗多发性骨髓瘤(MM)引起的周围神经病(bortezomib-induced peripheral neuropathy,BIPN)的临床效果及安全性。方法:采用单中心随机对照临床研究2012年7月至2016年5月我中心65例新诊断的MM患者,将他们分为2组,其中治疗组27例,采用静脉输注大剂量甲钴胺预防BIPN;对照组38例,未接受任何预防BIPN的药物。观察2组患者BIPN的发生率及其严重度并分析疗效、生存率及药物的不良反应。结果:治疗组和对照组患者年龄和性别比例均无统计学差异(P>0.05)。治疗组BIPN发生率(29.63%)明显低于对照组(55.26%)(χ~2=4.197,P<0.05),治疗组Ⅱ和Ⅲ级以上BIPN发生率分别为18.52%和3.71%,均明显低于较对照组(47.37%,21.05%)(χ~2=5.746,P<0.05;χ~2=3.983,P<0.05);2组因Ⅲ级及Ⅲ级以上程度BIPN导致未完成5个疗程Vel治疗的分析结果显示:治疗组为3.71%,低于对照组15.79%,但无明显统计学差异(χ~2=2.714,P>0.05)。治疗组和对照组的总有效率分别为77.78%和73.68%(P>0.05)。治疗组和对照组的PFS和OS均无统计学差异(P>0.05)。静脉输注大剂量甲钴胺的安全性的分析结果显示,治疗组3.71%患者出现轻度皮疹,无其它毒副作用发生。结论:大剂量静脉输注甲钴胺能有效预防BIPN发生,或减轻其严重程度,具有良好安全性。
Objective: To evaluate the efficacy and safety of high-dose intravenous mecobalamin (HDIME) for the treatment of bortezomib-induced peripheral neuropathy(BIPN) in the patients with multiple myeloma (MM). Methods: A total of 65 newly diagonsed patients with multiple myeloma receiving bortezomib in Tianjin Medical University General Hospital were enrolled in this single-centre randomized clinical trial from July 2012 to May 2016. Out of 65 patients 38 in control group received bortezomib - based chemotherapy and 27 patients in HDIME group received the additional high-dose intravenous mecobalamin. Results : The incidence of BIPN in HDIME group was lower than that in control group(29.63% vs 55.26% , χ^2 = 4. 197, P 〈 0.05 ). Whether the BIPN rate of Grade 2 or 3 and above in HDIME group significantly decreased as compared with control group ( 18.52% vs 47.37%, χ^2 = 5. 746, P 〈 0. 05 ) (3.71% vs 21.05%,χ^2 = 3. 983 ,P 〈 0.05 ). The BIPN rate of less than 5 cycles of bortezomib was not significantly different between HDIME and control groups ( χ^2 = 2.714, P 〉 0.05 ). Overall effective rate of HDIME group and control group was 77.78% and 73.68% (P 〉 0. 05 ) respectively. Neither PFS nor OS was significantly different between HDIME group and control group( P 〉 0.05 ). Treatmentrelated toxicity was only mild rash in 1 case. No other side - effects including nausea, abdominal pain, and hypotension occurred. Conelusion: HDIME has a good efficacy for the prophylaxis BIPN and and without serious side effects.
出处
《中国实验血液学杂志》
CAS
CSCD
北大核心
2017年第2期480-484,共5页
Journal of Experimental Hematology
基金
天津市自然科学基金(12JCZDJC21500
14JCYBJC25400)
天津市抗癌重大专项攻关计划(12ZCDZSY18000)
天津医科大学基金(2010ky20)